• Journal Article

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk

Citation

Samelson, E., Christiansen, C., Daizadeh, N., Grazette, L., Anthony, M., Egbuna, O., ... Kiel, D. (2014). RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. Journal of Bone and Mineral Research, 29(2), 450 - 7.

Abstract